Brief: Vicore Pharma Announces Effects Of VP01 On IPF Patient Tissue

Vicore Pharma Holding AB

25/09/2020 07:04

Sept 25 (Reuters) - Vicore Pharma Holding AB  VICOR.ST :
    * ROBUST EFFECTS OF VP01 IN HUMAN IDIOPATHIC PULMONARY
FIBROSIS
LUNG TISSUE
    * ANNOUNCES EFFECTS OF VP01 ON IDIOPATHIC PULMONARY FIBROSIS
(IPF)
PATIENT TISSUE
    * FRESH HUMAN IPF LUNG TISSUE HARVESTED FROM A PATIENT
DURING LUNG
TRANSPLANTATION SHOWED STABLE EXPRESSION OF VP01 TARGET,
ANGIOTENSIN TYPE 2 RECEPTOR (AT2R)
    * TREATMENT WITH CLINICALLY RELEVANT CONCENTRATIONS OF VP01
CAUSED
A DOSE-DEPENDENT DECREASE OF TGFB1, A KEY GROWTH FACTOR IN
FIBROSIS DEVELOPMENT

Source text for Eikon:  ID:nWkr1XY59R 
Further company coverage:  VICOR.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))